Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to 13th, 2024 at the Henry B. Gonzalez Convention Center in San Antonio, TX, USA.
SABCS is expected to attract around 10,000+ attendees from more than 102 countries, including oncologists, researchers, and healthcare professionals.
This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancerand premalignant breast disease to an international audience of academic and private physicians and researchers.
The scientific program includes:
– Formal lectures by experts in clinical, translational, and basic research
– Selected slide and poster presentations
– Forums and case discussions
The official language of the symposium is English, and simultaneous translation is not provided.
This international event primarily targets academic and private physicians, as well as researchers in medical, surgical, gynecologic, and radiation oncology, along with patient advocates and other relevant healthcare professionals.
“Saranya Chumsri, Brenda Ernst, Edith Perez, Tatiana Prowell, Debora Denardi, and Amylou Dueck discussed “Patient Driven Protocol Development” in a career development session at SABCS24.”
“We need to ask all patients on endocrine therapy for breast cancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from Jenni Sheng.”
“Heather Greenlee, Professor and Nathoropath at Fred Hutchinson Cancer Center: ‘just because something is natural, doesn’t mean it is safe'”
“Encouraging results with neo adjuvant HER3-Dxd with letrozole in neoadjuvant Hr positive and her2 negative EBC . We need to see if it changes EFS on longer follow up. Solti Valentine trial.”
“One of the most awaited LBA of SABCS24: Exploratory Biomarker Analysis of KEYNOTE-522 Several biomarkers were prognostic but not predictive of benefit with pembro: Higher TMB was associated with EFS T-cell inflamed GEP was associated with pCR and EFS.”
“Looking forward to SABCS24 General Session 1 – important updates for BRCA carriers:
– Super prof. Matteo Lambertini will present results on the role of risk-reducing surgeries on survival in young patients
– OlympiA updates.”
“It was wonderful to discuss about novel treatment options for ER+ Her-2 Negative.”
“SOLTI Valentine: HER3-DXd +/- ET or Chemo in HR+/HER2- high risk EBC.
pCR rates similar.
Yet, it’s a randomised noncomparative trial…is it legit to compare?
HER3-DXd is effective. IMO, we’ll need better EFS (or better QoL) for routine use (after a bigger trial).”
“A randomized, placebo-controlled trial in people with early breast cancer of FORT (cognitive-existential fear of recurrence therapy, given twice wkly x 6 wks) found that FORT decreased fear of BC recurrence both post-therapy and 3 mos later.”
“Brilliant questions from Ellen Landsberger – could we use ctDNA here? Right now NO surveillance tests are done based on studies showing no improvement in OS but the studies that led to this recommendation were done DECADES ago, with X-rays and ultrasound.”
“Well, it only took us [Insert indistinct grumbling about how long we have been coming to San Antonio] years to visit the Alamo—but look—we finally remembered! —with Kevin Kalinsky and Seth Wander.”
“Dr Heather Parsons on how we can use ctDNA to guide treatment. For me, targeting a mutation I have, discovered via liquid biopsy, seems to be working (for now, the anger will mutate again at some point)”
“Former Komen grantee Aditya Bardia presents new data from the phase 3 DESTINY-Breast06 trial SABCS24. Trastuzumab-deruxtecan results in better progression-free survival compared to chemotherapy in people with HER2-low/ultra-low breast cancer – even in aggressive cases.”
“LBA session: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06 presented by Aditya Bardia.”
“PADMA study: ET + palbo vs chemo (cape/taxane/navelbine) in high risk HR+ MBC–> confirms ET+ cdk4/6i is 1L SOC
n=150
42% with liver mets
6%BRCAm
TTF: 17.2 vs 6.1mo HR 0.46
PFS: 18.7 vs 7.8 mo, HR 0.45
OS trend: 46.1 vs 36.8 month”
“SABCS24 Day 1 Highlights Community Oncology:
1. FDA Oncology Reviews recent approvals: Ribociclib and Inavolisib
2. PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. DB06: HR+ TDXd
4. KN522: biomarker analysis
1. Recent FDA approvals:
a). NATALEE: Adj Ribociclib in HR+ Stg IIA – III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2. PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.
– SABCS22 in Right Choice study, we knew CDK4/6i upfront is better.
– Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3. DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
– Improved PFS regardless of time to progression on CDK4/6i or tumor burden
– PFS2 better with TDXd
– In what line will you use this.
4. KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC. – This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.”
“Biomarker analysis of KN522
Interesting potential predictors of increased Pembro benefit (e.g. TMB).
IMO, if confirmed, maybe could pave the way to chemotherapy intensity de-escalation in this population (~8% of total). Also interesting to study how this relates to TILs.”
“JUST NOW: Aditya Bardia presented the updated results of DESTINY-Breast06 at SABCS.”
“Educational Session 1: Mind the Gap – Breast Cancer in the Young chaired by Matteo Lambertini
‘Ovarian Suppression: Who, When, Why, and for How Long’ great presentation by Prudence Francis.”
“Why use OFS in ER negative Breast Cancer? It has benefits for survivorship of women. Great talk on OFS by the dazzling Prue Francis.”
“SABCS 2024 session Mind the Gap – Breast Cancer in the Youth chaired by Matteo Lambertini opened by an overview of Biology of Breast Cancer in Young Women, followed by Ovarian Suppression: Who, When, Why, and for How Long.”
“Our very own Ada Waks reports no sig difference in pCR with neoadjuvant TMP vs THP in stage II-III HER2+ BC with CD16A F in phase II MARGOT study. Interesting trend towards higher pCR with TMP in HR+ HER2+ BC with immune correlative studies pending.”
“MARGOT study: Preop THP vs TMP (M= margetuximab) in patients with a CD16AF alleleNo significant improvement in pCR with TMP c/w THP
n=171, pCR: 56% vs 46%, p=0.25
HR+ pCR 54% vs 35%, HR-: 60% vs 71%
Presented by the superstar Ada Waks.”
“Immediate surgery (as compared to deferring surgery until after progression) is associated with better outcomes in local recurrence, distant recurrence, and mortality in older women (70+).”
“LB1-01 – Immediate Breast Surgery Versus Deferral of Surgery in Women Aged 70+ Years with Operable Breast Cancer: Patient-Level Meta-Analysis of the Three Randomized Trials Among 1,082 Women by Robert Hills.”
“Story short, TDXd was better in all groups.
Quick or slow relapsers on DB-06
Regardless of disease burden
Among primary or secondary endocrine resistance.”
“Attending the SABCS24
Session about ctDNA and liquid biopsy. Great advances and promising tools for Patient Care.”
“Padma study shows that first line treatment of ER+ MBC is >> better than first line single agent chemo.”
“Robert Hills presents meta-analysis of 3 studies of > 1000 patients on immediate vs delayed surgery for early stage breast cancer. Immediate surgery reduces local recurrence and distant recurrence though occurs over longer follow up. Also reduced breast cancer mortality.”
“Designing Patient-centric Clinical Trials
Brilliant talk by Tatiana Prowell.”
Session on career development and patient driven protocol development.”
“Cowabunga! Riding Breast Cancer’s Biggest Data’s Wave from SABCS24.
SOLTI-VALANTINE:
New way for Neoadjuvant luminal BC:
Phase II
HER3-DXd +\- OT vs Chemo
simular pCR, but lower G3 tox.”
“Terrific ending for SABCS24 day 1 with an all round symposium on HR+/HER2- MBC. Learned so much from Drs. MacGregor and Juric. Thanks for all the in-person and virtual attendees and to the MedscapeLIVE team!”
“Thrilled to kick off SABCS24 on a high note with the Coltman Scholar Award Notification! Grateful for this honor and excited to connect with friends and collaborators!”
Further Reading:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023